









Markets
/
Stocks
/
nasdaq-nktr
/

Nektar Therapeutics

NKTR

36.810USD

+1.690+4.81%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

723.41MMarket Cap

LossP/E TTM



Nektar Therapeutics

36.810

+1.690+4.81%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Nektar Therapeutics

Currency: USD Updated: 2026-02-06

Key Insights

Nektar Therapeutics's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 83 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 114.43.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nektar Therapeutics's Score

Industry at a Glance

Industry Ranking

83 / 392

Overall Ranking

208 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Nektar Therapeutics Highlights

StrengthsRisks

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Growing

The company is in a growing phase, with the latest annual income totaling USD 98.43M.

Undervalued

The company’s latest PE is -4.87, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 14.85M shares, increasing 13.99% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 278.54K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.66.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

114.429

Target Price

+204.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Nektar Therapeutics is 5.72, ranking 333 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 11.79M, representing a year-over-year decrease of 51.13%, while its net profit experienced a year-over-year decrease of 4.14%.

Score

Industry at a Glance

Previous score

5.72

Change



Financials

4.71

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.07

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.90

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Nektar Therapeutics's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Nektar Therapeutics is 6.87, ranking 208 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.87, which is -99.67% below the recent high of -0.02 and -78.46% above the recent low of -8.70.

Score

Industry at a Glance

Previous score

6.87

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 83/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Nektar Therapeutics is 8.75, ranking 61 out of 392 in the Biotechnology & Medical Research industry. The average price target is 105.00, with a high of 121.00 and a low of 98.00.

Score

Industry at a Glance

Previous score

8.75

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

114.429

Target Price

+204.01%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Nektar Therapeutics

NKTR

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Nektar Therapeutics is 7.47, ranking 70 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 41.33 and the support level at 32.84, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.05

Change

0.42

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(5)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

1.039

Neutral

RSI(14)

42.663

Neutral

STOCH(KDJ)(9,3,3)

52.812

Neutral

ATR(14)

2.456

Low Volatility

CCI(14)

-61.207

Neutral

Williams %R

46.299

Neutral

TRIX(12,20)

-0.760

Sell

StochRSI(14)

62.184

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

37.309

Sell

MA10

37.022

Sell

MA20

37.060

Sell

MA50

45.152

Sell

MA100

51.623

Sell

MA200

36.103

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Nektar Therapeutics is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 73.02%, representing a quarter-over-quarter increase of 41.88%. The largest institutional shareholder is The Vanguard, holding a total of 1.02M shares, representing 5.03% of shares outstanding, with 23.97% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BVF Partners L.P.

1.28M

The Vanguard Group, Inc.

Star Investors

948.65K

+30.04%

Susquehanna International Group, LLP

924.90K

+316.82%

Morgan Stanley & Co. LLC

883.58K

+1357.26%

Farallon Capital Management, L.L.C.

791.00K

Two Sigma Investments, LP

613.14K

+672.27%

Emerald Advisers LLC

556.45K

+220.00%

Millennium Management LLC

545.99K

-15.88%

BlackRock Institutional Trust Company, N.A.

476.31K

+59.94%

Nantahala Capital Management, LLC

418.52K

-41.03%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Nektar Therapeutics is 4.35, ranking 91 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Nektar Therapeutics’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.